

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**INSIDE INFORMATION — INCLUSION OF UNVERIFIED LIST
BY U.S. COMMERCE DEPARTMENT
AND
RESUMPTION OF TRADING**

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Reference is made to the announcement in relation to the trading halt published at 11:52 a.m. on February 8, 2022 by the Company.

On February 8, 2022, the Company noted that the Bureau of Industry and Security in the Department of Commerce of the United States of America (the “**U.S. Commerce Department**”) added two of its subsidiaries, namely, WuXi Biologics Co., Ltd. and WuXi Biologics (Shanghai) Co., Ltd. (together, the “**Subsidiaries**”), to the Unverified List. The Company understands that the inclusion of the Subsidiaries on the Unverified List is because the relevant U.S. government agencies have not been able to undertake the required end-use verifications in order for certain equipment to be exported from U.S. suppliers. The Unverified List is different from the Entity List. Listing on the Unverified List does not mean that U.S. exporters cannot engage with the listed parties or that there are specific, valuable, articulable national security or foreign policy concerns with those parties.

The Company has been importing certain hardware controllers for bioreactors and certain hollow fiber filters that are subject to U.S. export controls and have received approvals from the U.S. Commerce Department for the past 10 years in accordance with the applicable U.S. export control regulations. The Company is of the view that this incident has no material adverse effect on its business or ongoing services to its global partners, and that the impact to its imports is not significant, as such imported equipment is not required after the construction of facilities in Shanghai and Wuxi. Nevertheless, the Company is pursuing interim measures to request for the removal of the Subsidiaries from the Unverified List. The Company will make further announcements as and when appropriate in accordance with the Listing Rules and the SFO in the event of any material development of the above matter.

Trading in the shares of the Company on the Stock Exchange was halted with effect from 10:51 a.m. on Tuesday, February 8, 2022 pending the release of this announcement. An application has been made to the Stock Exchange for resumption of trading in the shares of the Company with effect from 9:00 a.m. on Wednesday, February 9, 2022.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, February 8, 2022

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.

* *For identification purpose only*